Cimetidine does not alter atorvastatin pharmacokinetics or LDL- cholesterol reduction

European Journal of Clinical Pharmacology

Volumn 53, Issue 6, 1998, Pages 475-478

  Stern, R H ^a   Gibson, D M ^a   Whitfield, L R ^a  

^a PFIZER INC   (United States)

Author keywords

Atorvastatin; Cimetidine

Indexed keywords

ATORVASTATIN; CIMETIDINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CLINICAL TRIAL; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG EFFECT; DRUG POTENCY; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0031979788     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050409     Document Type: Article

References (11)

1. Cilla DD, Whitfield LR, Gibson DM, Sedman AJ, Posvar EL (1996) Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects. Clin Pharmacol Ther 60: 687-695
2. Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupien PJ, Jones PH, Haber HE, Black DM (1995) Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 15: 678-682
3. Spatzenegger M, Jaeger W (1995) Clinical importance of hepatic cytochrome P450 in drug metabolism. Drug Metab Rev 27: 397-417
4. Shinn AF (1992) Clinical relevance of cimetidine drug interactions. Drug Safety 7: 245-267
5. Shum YY, Huang H (1993) Development and validation of an enzyme inhibition assay for quantitation of CI-981 in human plasma. Pharm Res 10: S-415
6. Cilla DD, Gibson DM, Whitfield LR, Sedman AJ (1996) Pharmacodynamic effects and pharmacokinetics of atorvastatin following drug administration to normocholesterolemic subjects in the morning and evening. J Clin Pharmacol 36: 604-609
7. Physicians' desk reference, 50th edition Medical Economics, (1996) Montvale, NJ
8. Smith SJ, Cooper GR, Myers GL, Sampson EJ (1993) Biological variability in concentrations of lipids: sources of variation among results from published studies and composite predicted values. Clin Chem 39: 1012-1022
9. Henkin Y, Como JA, Oberman A (1992) Secondary dyslipidemia inadvertent effects of drugs in clinical practice. JAMA 267: 961-968
10. TB (CYP2C9) by (+/-)-fluvastatin. Clin Pharmacol Ther 58: 412-7
11. Vyas KP, Kari PH, Wang RW, Lu AYH (1990) Biotransformation of lovastatin III. Effect of cimetidine and famotidine on in vitro metabolism of lovastatin by rat and human liver microsomes. Biochem Pharmacol 39: 67-73